- Home
- UBX vs BNR Comparison
UBX vs BNR Comparison
Compare UBX & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBX
- BNR
- Stock Information
- Founded
- UBX 2009
- BNR 2014
- Country
- UBX United States
- BNR China
- Employees
- UBX N/A
- BNR N/A
- Industry
- UBX Biotechnology: Pharmaceutical Preparations
- BNR Medical Specialities
- Sector
- UBX Health Care
- BNR Health Care
- Exchange
- UBX Nasdaq
- BNR Nasdaq
- Market Cap
- UBX 24.6M
- BNR 28.6M
- IPO Year
- UBX 2018
- BNR 2020
- Fundamental
- Price
- UBX $1.26
- BNR $3.75
- Analyst Decision
- UBX Strong Buy
- BNR
- Analyst Count
- UBX 3
- BNR 0
- Target Price
- UBX $9.00
- BNR N/A
- AVG Volume (30 Days)
- UBX 70.7K
- BNR 21.3K
- Earning Date
- UBX 11-04-2024
- BNR 11-29-2024
- Dividend Yield
- UBX N/A
- BNR N/A
- EPS Growth
- UBX N/A
- BNR N/A
- EPS
- UBX N/A
- BNR N/A
- Revenue
- UBX N/A
- BNR $70,154,674.00
- Revenue This Year
- UBX N/A
- BNR $52.90
- Revenue Next Year
- UBX N/A
- BNR $48.35
- P/E Ratio
- UBX N/A
- BNR N/A
- Revenue Growth
- UBX N/A
- BNR N/A
- 52 Week Low
- UBX $1.11
- BNR $2.62
- 52 Week High
- UBX $2.26
- BNR $9.99
- Technical
- Relative Strength Index (RSI)
- UBX 47.73
- BNR 59.38
- Support Level
- UBX $1.11
- BNR $3.50
- Resistance Level
- UBX $1.37
- BNR $3.89
- Average True Range (ATR)
- UBX 0.08
- BNR 0.27
- MACD
- UBX 0.00
- BNR 0.12
- Stochastic Oscillator
- UBX 69.49
- BNR 82.19
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.